1. In Vivo
  2. >>Innovation

FoxHollow Makes First Acquisition, Buys Kerberos

After much anticipation, atherectomy leader FoxHollow Technologies has finally joined the ranks of the acquirers, buying Kerberos Proximal Solutions, maker of the Rinspiration system, which is a catheter-based system that both rinses and aspirates vessels to remove blood clots and soft emboli. Both companies are currently focusing on treating peripheral vascular disease.

After much anticipation, atherectomy leader FoxHollow Technologies Inc. has finally joined the ranks of the acquirers. Since the dramatic four-fold run-up in the company’s stock price that occurred following its October 2004 IPO, peaking one year later at $54.04 per share with a market cap upwards of $1.2 billion, the medical device industry has been waiting for the company to leverage that added value and broaden its limited product line through acquisitions. [See Deal] Nearly one year later, that has finally happened: FoxHollow will acquire Kerberos Proximal Solutions Inc. [See Deal]

FoxHollow’s notable success has been the result of shifting the focus of its SilverHawk atherectomy device for removing plaque from...

More from Innovation

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By Jo Shorthouse

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Trojan Bio Eyes Perfect Rainbow Shot With Immune System Cancer Innovations

 
• By Ashley Yeo

Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 
• By Edwin Elmhirst

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.